Therapeutics Symposium
From Basic Research to Drugs in Patients
17th November 2016

9.00                    Registration
9.30-9.45               Introduction Tony Kouzarides

Session 1, Chair: Mathew Garnett
9.45-10.15              Bill Sellers (Formerly Novartis) - Linking the discovery of cancer vulnerabilities to therapeutic development
10.15-10.35             Susan Galbraith (AstraZeneca) - AZ Oncology Innovative Medicines - Focus on DNA Damage and Cell Death
10.35-11.05             Charles Swanton (Francis Crick Institute) - Chromosomal Chaos and Cancer Evolution

Coffee

Session 2, Chair: Susan Galbraith
11.30-12.00             David Rubinsztein (CIMR) - Autophagy and related pathways that protect against urodegeneration
12.00-12.20             Rab Prinjha (GSK) - Epigenetic Targets for the Treatment of Human Diseases
12.20-12.50             Peter McNaughton (King’s College London) - Development of selective blockers of HCN2 ion channels as novel analgesics
12.50-13.10             Nick Pullen (Pfizer) - Building the next innovative therapies in inflammation & fibrosis

Lunch

Session 3, Chair: Gerard Evan
2.30-3.00               Molly Stevens (Imperial College London) - Designing materials to detect disease and heal the body
3.00-3.20               Harren Jhoti (Astex) - Fragment-Based Drug Discovery: the advantage of thinking small
3.20-3.40               Tsuneaki Sakata (Shionogi) - R&D Focus - Infectious Diseases
3.40-4.10               Allan Bradley (Sanger Institute) - Complete humanisation of the mouse immunoglobulin loci for therapeutic antibody discovery

4.10-4.15               Concluding Remarks Tony Kouzarides
4:15-6:00               Posters and Drinks